PDVAC Executive summary 2020: The Vaccine Innovation Prioritisation Strategy (VIPS)

Overview

2020 WHO Product Development for Vaccines Advisory Committee (PDVAC) Virtual Consultation 5: VIPS: 8 July 2020

The scope of VIPS includes completely new product presentations and packaging, or adaptations to existing products that could provide measurable financial or programmatic benefits to LMICs, such as increased coverage and equity, or vaccine effectiveness. The VIPS process was designed and implemented by a working group composed of members from each of the VIPS partners, with oversight from an expert steering committee. The process concluded in May
2020 with a decision to prioritise 3 innovations / approaches for which the Alliance will engage to advance
development, policy, and access.